21:32 , Apr 18, 2018 |  BC Extra  |  Preclinical News

Study challenges FCGR2A as latent HIV marker

A paper in Science Translational Medicine suggests the T cell surface receptor Fc gamma receptor IIa (FCGR2A; CD32A) is a marker of T cells that are actively infected with HIV, rather than those with latent...
00:05 , Mar 16, 2017 |  BC Extra  |  Clinical News

Paper ties new target to latent HIV infection in T cells

In a paper published Wednesday in Nature , a French team led by researchers at the University of Montpellier discovered that a surface receptor on T cells, Fc gamma receptor IIa ( FCGR2A ; CD32A),...
07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD40; Fcγ receptor IIb (FCγR2B; CD32B); FCγR2A (CD32A)

Cancer INDICATION: Cancer In vitro and mouse studies suggest a CD40-targeting mAb with greater affinity for FCγR2B than for FCγR2A could help treat cancer. In in vitro binding assays, a variant of the CD40-agonizing mAb...
08:00 , Jan 15, 2015 |  BC Innovations  |  Tools & Techniques

Boosting IgG with IgA

Although all marketed therapeutic mAbs use an IgG backbone, mostly for pharmacokinetic reasons, the antibodies don't do a good job of inducing neutrophils to kill cancer cells. A group at the University of Texas at...
08:00 , Dec 1, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiovascular disease Fc g-receptor IIa (CD32A; FCGR2A) A genomewide association study identified a SNP in FCGR2A that could help predict susceptibility to Kawasaki disease,...
08:00 , Feb 25, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myeloid leukemia (AML) Fc g-receptor IIa (CD32A; FCGR2A) IL-2 receptor a-chain (CD25) Studies of human serum samples and of mice suggest that inhibiting CD32A...
08:00 , Dec 3, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Gastrointestinal disease Colitis Fc g-receptor IIa (CD32A; FCGR2A); solute carrier family 26 member 3 (SLC26A3) A genomewide association study identified three SNPs that could help predict...
07:00 , Jul 21, 2008 |  BioCentury  |  Strategy

Raven's better roost

MacroGenics Inc. hopes that its acquisition of Raven Biotechnologies Inc. will create a soup-to-nuts cancer antibody play. The deal, for an undisclosed amount of stock, combines MacroGenics' mAb engineering technologies with Raven's mAb generation platform....
07:00 , Jun 19, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Fc g-receptor IIa (FCGR2A; CD32A); Fc g-receptor IIIb (FCGR3B; CD16) A study suggests that antagonizing FCGR2A on...
07:00 , Oct 10, 2005 |  BC Week In Review  |  Company News

Prima, Trillium Therapeutics deal

Trillium acquired PRR's Arthron subsidiary for $500,000 in cash and 1.2 million Trillium shares, which represents a 7% stake in the company. PRR is slated to receive an additional $75,000 in cash from Trillium next...